Objective:To screen and identify the key active molecules,signaling pathways,and therapeutic targets of Shuxuening(SXN)injection for treating liver cirrhosis(LC)and to evaluate its therapeutic potential using a mouse ...Objective:To screen and identify the key active molecules,signaling pathways,and therapeutic targets of Shuxuening(SXN)injection for treating liver cirrhosis(LC)and to evaluate its therapeutic potential using a mouse model.Methods:Target genes of SXN and LC were retrieved from public databases,and enrichment analysis was performed.A proteineprotein interaction(PPI)network was constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins(STRING),and hub genes were identified using Molecular Complex Detection(MCODE).LC was induced in rats and mice via intraperitoneal injections of diethylnitrosamine and carbon tetrachloride(CCl4)for 12 weeks.Starting at week 7,SXN was administered intraperitoneally to the mice in the treatment group.Serum and liver tissues of the mice were collected for the detection of indicators,pathological staining,and expression analysis of hub targets using quantitative real-time polymerase chain reaction(qRT-PCR).Results:We identified 368 overlapping genes(OLGs)between SXN and LC targets.These OLGs were subsequently used to build a PPI network and to screen for hub genes.Enrichment analysis showed that these genes were associated with cancer-related pathways,including phosphoinositide-3-kinase/Akt and mitogen-activated protein kinase signaling and various cellular processes,such as responses to chemicals and metabolic regulation.In vivo experiments demonstrated that SXN treatment significantly improved liver function and pathology in CCl4-induced LC mice by reducing inflammation and collagen deposition.Furthermore,qRT-PCR demonstrated that SXN regulated the expression of MAPK8,AR and CASP3 in the livers of LC mice.Conclusion:This study highlighted the therapeutic effects of SXN in alleviating LC using both bioinformatics and experimental methods.The observed effect was associated with modulation of hub gene expression,particularly MAPK8,and CASP3.展开更多
OBJECTIVE: To systematically investigate the safety of Xingxue~ Shuxuening injection(SXN) in preand post-marketing, and to ensure clinical drug safety.METHODS: Strict quality control in raw herb selection and producti...OBJECTIVE: To systematically investigate the safety of Xingxue~ Shuxuening injection(SXN) in preand post-marketing, and to ensure clinical drug safety.METHODS: Strict quality control in raw herb selection and production processes was adopted and pharmacology research on SXN was performed by the drug manufacturing company, Heilongjiang ZBD Pharmaceutical Co., Ltd. We systematically reviewed the safety literature of Xingxue~ SXN. Adverse drug reaction(ADR) data of the drug, extracted from Spontaneous Reporting System(SRS), and clinical characters based on 20 hospital information systems(HIS) in China, were analyzed. Large-scale prospective safety monitoring and Risk Minimization Action Plans(Risk MAPs) of Xingxue~SXN were carried out.RESULTS: The quality of SXN was stable and controllable when it was produced. Drug toxicology studies found no effect on rabbits with hemolytic or condensed, local stimulation and muscle stimulation, and no allergic reactions in guinea pigs. The ADRs of Xingxue~ SXN were dizziness, phlebitis,and vomiting based on SRS data. The injection did not conform to instructions in clinical practice when we analyzed HIS database, and patient’s abnormal blood urea nitrogen levels may be related to the drug, when analyzed using the propensity score method. A nested case-control study was designed and performed to analyze the influencing factors of suspected allergic reactions to SXN. The study showed that patients with an allergy history were more prone to allergic reactions(P<0.001),and some medicine combinations could cause allergic reactions.CONCLUSION: These studies have established a body of evidence on Xingxue~ SXN safety, and provide a good model for Chinese medicine injection for clinical safety. The Xingxue~ SXN production process and toxicology research indicate the safety of the injection. However, the use of the injection is not consistent with instructed clinical practice.Xingxue~ SXN causes ADRs perhaps from inappropriate usage or its pharmacological action. This injection needs better Risk MAPs to ensure its clinical safety.展开更多
Objective:To study the effect of adjuvant Shuxuening injection therapy on the inflammatory response mediated by TLRs in patients with acute exacerbation of COPD.Methods:Patients with acute exacerbation of COPD who rec...Objective:To study the effect of adjuvant Shuxuening injection therapy on the inflammatory response mediated by TLRs in patients with acute exacerbation of COPD.Methods:Patients with acute exacerbation of COPD who received Shuxuening injection combined with conventional western medicine treatment in our hospital between May 2014 and December 2015 were selected for study, and before treatment as well as 1 week, 2 weeks, 3 weeks and 4 weeks after treatment, peripheral blood mononuclear cells were collected to determine TLRs expression, and serum was collected to determine the levels of inflammatory cytokines and airway remodeling molecules.Results:1 week, 2 weeks, 3 weeks and 4 weeks after treatment, TLR2 and TLR4 mRNA expression in peripheral blood mononuclear cells as well as TNF-α, IL-6, MCP-1, VCAM-1, MMP2, MMP9, TGF-β and BMP-2 levels in serum of patients with COPD were significantly lower than those before treatment, and TLR3, TLR7, TLR8 and TLR9 mRNA expression were not significantly different from those before treatment;TLR2 and TLR4 mRNA expression in peripheral blood mononuclear cells were positively correlated with serum TNF-α, IL-6, MCP-1, VCAM-1, MMP2, MMP9, TGF-β and BMP-2 levels. Conclusion:Adjuvant Shuxuening injection therapy has significant inhibitory effect on the inflammatory response mediated by TLRs in patients with acute exacerbation of COPD.展开更多
Background:To systematically evaluate the efficacy and safety of the Chinese patent medicine Shuxuening injection combined with western medicine in vascular dementia treatment.Methods:Randomized controlled trials of t...Background:To systematically evaluate the efficacy and safety of the Chinese patent medicine Shuxuening injection combined with western medicine in vascular dementia treatment.Methods:Randomized controlled trials of the Chinese patent medicine Shuxuening injection in vascular dementia treatment is searched in the databases of CNKI,Wanfang,VIP,CBM,PubMed,The Cochrane Library,Embase and Web of Science from the establishment time to December 2020.After screen the literature,extract the data and evaluate the bias risk of studies included;tRevMan5.3 was used for met-analysis.Results:Nine randomized controlled trials including 932 patients were included.The results of meta-analysis included:(1)the total effective rate(RR=1.27,95%CI(1.18,1.36),P<0.00001);(2)MMSE score(MD=4.78,95%CI(1.75,7.80),P=0.002);(3)ADL score(MD=8.87,95%CI(6.70,11.05),P<0.00001);(4)NIHSS score(MD=−6.60,95%CI(−7.04,−6.16).P<0.00001).The results of meta-analysis of the test group are better than those in the control group.Conclusion:The Chinese patent medicine Shuxuening injection combined with conventional western medicine has showed some advantages in the total effective rate,MMSE score,ADL score,NIHSS score than conventional western medicine without more side effects in vascular dementia treatment.More randomized,double-blind,large sample clinical studies are needed to confirm the above conclusions.展开更多
OBJECTIVE: To observe the effect of Shuxuening Injection combined with alprostadil on healing of diabetic foot ulcers and hemodynamic indexes of dorsal artery of foot. METHODS: A total of 84 cases of diabetic foot pat...OBJECTIVE: To observe the effect of Shuxuening Injection combined with alprostadil on healing of diabetic foot ulcers and hemodynamic indexes of dorsal artery of foot. METHODS: A total of 84 cases of diabetic foot patients treated in Wuhan Red Cross Hospital(from February 2016 to April 2017) were divided into treatment group(42 cases) and control group(42 cases) by the random digital table. The control group was given basic clinical treatment while the treatment group was given Shuxuening Injection combined with alprostadil on the basis of the treatment in control group. After 2 weeks of treatment, the improvement of TCM symptom scores(pain, numbness, swelling, claudication), conditions of foot ulcer healing(ulcer area, wound oxygen pressure, wound pH), the hemodynamics of the dorsum pedis artery(the blood flow velocity of the dorsum pedis artery, the blood vessel diameter, resistance index(RI), pulsation index(PI)) of both groups were compared, and the clinical efficacy of 2 groups were statistically analyzed. RESULTS: The scores of pain, numbness, swelling and claudication were significantly reduced in 2 groups after the treatment(P < 0.05), and the improvement of the above symptom scores in the treatment group were all significantly better than that in the control group(P < 0.05). The area of ulcer and the p H of the wounds in the 2 groups were significantly decreased after the treatment(P < 0.05), and the oxygen partial pressure in the wound was significantly increased(P < 0.05), and the improvements of the wound healing outcomes in the treatment group were significantly better than that in the control group(P < 0.05). The blood flow velocity of the foot, the blood vessel diameter, the level of RI and PI after treatment in both groups were significantly increased after the treatment(P < 0.05), and the improvement of the hemodynamic index of the foot back after treatment in the treatment group was significantly better than that in the control group(P < 0.05). The total effective rate of the treatment group was significantly higher than that of the control group(P < 0.05). CONCLUSION: The application of Shuxuening Injection combined with alprostadil can quickly improve the clinical symptoms of the patients, correct the abnormal hemodynamics of the dorsum pedis artery and promote the healing of foot ulcers, and the combination of the two medicines has a synergistic effect.展开更多
Objective: to observe the clinical effect of intravenous thrombolysis with alteplase combined with Shuxuening injection on ischemic stroke. Methods: selected subjects: 90 patients with acute ischemic stroke in the eme...Objective: to observe the clinical effect of intravenous thrombolysis with alteplase combined with Shuxuening injection on ischemic stroke. Methods: selected subjects: 90 patients with acute ischemic stroke in the emergency department of our hospital were selected from March 2021 to August 2022. They were grouped according to the computer parity distribution method, the control group database (45 patients data), and the observation group database (43 patients data), and Shuxuening injection combined with alteplase therapy. To observe the effects of different therapies on the clinical effect, neurological function score, inflammatory value, neurotransmitter and coagulation value of patients. Results: compared with the parameter difference between groups, there was no significant difference in data before treatment (P > 0.05). After treatment, the results of data comparison were significant, the clinical treatment effect of the patients in the observation group was significantly improved, the inflammatory values and neurological function scores were significantly decreased, and the neurotransmitters and coagulation values were significantly improved, P<0.05. Conclusion: the combined therapy of intravenous thrombolysis with alteplase and Shuxuening injection for patients with acute ischemic stroke has a significant clinical effect, which can effectively change the patients condition and improve the inflammatory response and neurological function.展开更多
Objective: To investigate the main components and potential mechanism of Shuxuening Injection(SXNI) in the treatment of myocardial ischemia-reperfusion injury(MIRI) through network pharmacology and in vivo research. M...Objective: To investigate the main components and potential mechanism of Shuxuening Injection(SXNI) in the treatment of myocardial ischemia-reperfusion injury(MIRI) through network pharmacology and in vivo research. Methods: The Traditional Chinese Medicine Systems Pharmacology(TCMSP) and Pharm Mapper databases were used to extract and evaluate the effective components of Ginkgo biloba leaves, the main component of SXNI. The Online Mendelian Inheritance in Man(OMIM) and Gene Cards databases were searched for disease targets and obtain the drug target and disease target intersections. The active ingredient-target network was built using Cytoscape 3.9.1 software. The STRING database, Metascape online platform, and R language were used to obtain the key targets and signaling pathways of the anti-MIRI effects of SXNI. In order to verify the therapeutic effect of different concentrations of SXNI on MIRI in rats, 60 rats were first divided into 5 groups according to random number table method: the sham operation group, the model group, SXNI low-dose(3.68 mg/kg), medium-dose(7.35 mg/kg), and high-dose(14.7 mg/kg) groups, with 12 rats in each group. Then, another 60 rats were randomly divided into 5 groups: the sham operation group, the model group, SXNI group(14.7 mg/kg), SXNI+LY294002 group,and LY294002 group, with 12 rats in each group. The drug was then administered intraperitoneally at body weight for 14 days. The main biological processes were validated using in vivo testing. Evans blue/triphenyltetrazolium chloride(TTC) double staining, hematoxylin-eosin(HE) staining, terminal deoxynucleotidyl transferase d UTP nick end labeling(TUNEL) assay, enzyme-linked immunosorbent assay(ELISA), and Western blot analysis were used to investigate the efficacy and mechanism of SXNI in MIRI rats. Results: Eleven core targets and 30 Kyoto Encyclopedia of Genes and Genomes(KEGG) pathways were selected. Among these, the phosphoinositide 3-kinase(PI3K)/protein kinase B(AKT) pathway was closely related to SXNI treatment of MIRI. In vivo experiments showed that SXNI reduced the myocardial infarction area in the model group, improved rat heart pathological damage, and reduced the cardiomyocyte apoptosis rate(all P<0.01). After SXNI treatment, the p-PI3K/PI3K and p-AKT/AKT ratios as well as B-cell lymphoma-2(Bcl-2) protein expression in cardiomyocytes were increased, while the Bax and cleaved caspase 3 protein expression levels were decreased(all P<0.05). LY294002 partially reversed the protective effect of SXNI on MIRI. Conclusion: SXNI protects against MIRI by activating the PI3K/AKT signaling pathway.展开更多
Objective： To investigate the efficacy and safety of combined common femoral artery （CFA） endarterectomy with superficial femoral artery （SFA） stenting plus Shuxuening Injection （舒血宁注射液） infusion in patie...Objective： To investigate the efficacy and safety of combined common femoral artery （CFA） endarterectomy with superficial femoral artery （SFA） stenting plus Shuxuening Injection （舒血宁注射液） infusion in patients with complex multifocal arterial steno-obstructive lesions of the lower extremities. Methods： From March 2006 to March 2011, 104 lower limbs in 96 patients with multilevel peripheral arterial steno-occlusive disease, involving SFA as well as CFA and deep femoral artery （DFA） orifice, were treated by combined surgical with endovascular therapy, such as SFA stenting as an adjunct to CFA endarterectomy and patch angioplasty with the great saphenous vein. Before the end of the operation, 20 mL of Shuxuening Injection was infused through the catheter located in the treated artery. Technical and hemodynamic success, as well as primary and primary-assisted patency, was determined according to the Society for Vascular Surgery Guidelines. During follow-up, clinical status assessment, ankle-brachial index （ABI） test, and duplex Doppler ultrasound were administered every 6 months, and computed tomography angiography or magnetic resonance angiography was performed at 12, 24, and 36 months after discharge. Results： All patients underwent successful combined CFA endarterectomy with SFA stenting treatment. The average ABI after the combination treatment increased from pretreatment of 0.32 ± 0.21 to 0.82±0.24 （P〈0.01）. No perioperative death and major limb amputations occurred. The mean duration of follow-up for 104 limbs from 96 patients was 1,180 days （range, 196-2,064 days）. During follow-up, 5 patients died due to myocardial infarction, cerebral infarction, or pneumonia, and 5 patients were lost to follow-up. There were 21 cases （21.4%） of restenosis, with 15 that occurred in-stent and 6 near the dJstal end of the stent. A total of 18 （18.3%） reinterventions were performed, including 6 balloon angioplasty, 8 restenting procedures, 2 bypass surgeries, and 2 major limb amputations： The primary patency rates were 92.2%, 76.8%, and 61.3% at 12, 24, and 36 months, respectively, while the primary-assisted patency rates were 94.4%, 83.2%, and 75.6% at 12, 24, and 36 months, respectively. Conclusion： The combined CFA endarterectomy with SFA stenting plus Shuxuening Injection infusion appears to offer a safe, less invasive, and effective treatment option to patients with chronic lower extremity ischemia due to complex multifocal peripheral artery disease.展开更多
Objective: To make a preliminary evaluation of the clinical efficacy of Shuxuening (SXN).Methods: One hundred and forty-nine chronic schizophrenic patients were divided randomly into the SXN group and the control grou...Objective: To make a preliminary evaluation of the clinical efficacy of Shuxuening (SXN).Methods: One hundred and forty-nine chronic schizophrenic patients were divided randomly into the SXN group and the control group in a double-blind research. SXN was given to the SXN group and placebo to the control group, and patients of both groups went on receiving the previous antipsychotic treatment. Brief Psychiatric Rating Scale (BPRS), Scale for Assessment of Negative Symptoms (SANS) and Treatment Emergent Symptoms Scale (TESS) were used to assess the effects of treatment and side effects of the drug. The evaluation was done before and during the 2nd, 4th, 6th, 10th and 12 th weeks in the course of treatment. Results: SXN was effective by BPRS evaluation (P ＜0. 05), and even the more effective to negative symptoms than positive symptoms by SANS evaluation (P＜0. 05). It was safe and with little side effect. In addition, it was found that the incipience of SXN ’s efficacy was somehow related with the course of disease and the daily dosage used. Conclusion: SXN is worthy of further study n the treatment of chronic schizophrenia.展开更多
Objective:In this study,a comprehensive and effective quality method for evaluating the efficacy of ShuXueNing injection(SXNI)was developed.Materials and Methods:Quantitative high-performance liquid chromatography fin...Objective:In this study,a comprehensive and effective quality method for evaluating the efficacy of ShuXueNing injection(SXNI)was developed.Materials and Methods:Quantitative high-performance liquid chromatography fingerprint,the quantitative analysis of multicomponents by a single marker(QAMS)method,hierarchical cluster analysis(HCA),and orthogonal partial least squares discrimination analysis(OPLS-DA)were used to distinguish 53 batches of SXNI samples from 7 manufacturers.Results:A total of 53 batches of samples were analyzed to establish antithesis fingerprint of SXNI,and 12 peaks of the common model were collected and used for the similarity analysis.Meanwhile,six index flavonoid components were determined by the QAMS method,using rutin as internal reference substance.The accuracy of the QAMS method was confirmed by investigating the relative deviation between the QAMS method and the traditional external standard method.The results demonstrated that there was no significant difference(RE<1%),suggesting that QAMS was a reliable and convenient method for the content determination of multiple components.The HCA and OPLS-DA methods drew a similar conclusion.The 53 batches of SXNI samples from 7 manufacturers were categorized into five groups,indicating that chemometrics could reveal the quality differences of SXNI between the manufacturers.Conclusions:The method established herein was efficient and successful in assessing the quality of SXNI,and that it may be potentially employed in the quality control of related products composed of Ginkgo biloba extract.展开更多
基金Our study was funded by the Clinical Research Special Fund of Wu Jieping Medical Foundation(320.6750.2022-25-8)the Fundamental Research Funds for the Cornell University(2024-JYBXJSJJ042 and 2024-JYB-JBZD-058).
文摘Objective:To screen and identify the key active molecules,signaling pathways,and therapeutic targets of Shuxuening(SXN)injection for treating liver cirrhosis(LC)and to evaluate its therapeutic potential using a mouse model.Methods:Target genes of SXN and LC were retrieved from public databases,and enrichment analysis was performed.A proteineprotein interaction(PPI)network was constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins(STRING),and hub genes were identified using Molecular Complex Detection(MCODE).LC was induced in rats and mice via intraperitoneal injections of diethylnitrosamine and carbon tetrachloride(CCl4)for 12 weeks.Starting at week 7,SXN was administered intraperitoneally to the mice in the treatment group.Serum and liver tissues of the mice were collected for the detection of indicators,pathological staining,and expression analysis of hub targets using quantitative real-time polymerase chain reaction(qRT-PCR).Results:We identified 368 overlapping genes(OLGs)between SXN and LC targets.These OLGs were subsequently used to build a PPI network and to screen for hub genes.Enrichment analysis showed that these genes were associated with cancer-related pathways,including phosphoinositide-3-kinase/Akt and mitogen-activated protein kinase signaling and various cellular processes,such as responses to chemicals and metabolic regulation.In vivo experiments demonstrated that SXN treatment significantly improved liver function and pathology in CCl4-induced LC mice by reducing inflammation and collagen deposition.Furthermore,qRT-PCR demonstrated that SXN regulated the expression of MAPK8,AR and CASP3 in the livers of LC mice.Conclusion:This study highlighted the therapeutic effects of SXN in alleviating LC using both bioinformatics and experimental methods.The observed effect was associated with modulation of hub gene expression,particularly MAPK8,and CASP3.
基金Supported by National Science and Technology Major Projects for "Major New Drugs Innovation and Development:Study on Key Technologies of Post-marketing Evaluation for Chinese Medicine(No.2009ZX09502-030)"Doctoral Candidate Innovation Personnel Training Funding in China Academy of Chinese Medical Sciences
文摘OBJECTIVE: To systematically investigate the safety of Xingxue~ Shuxuening injection(SXN) in preand post-marketing, and to ensure clinical drug safety.METHODS: Strict quality control in raw herb selection and production processes was adopted and pharmacology research on SXN was performed by the drug manufacturing company, Heilongjiang ZBD Pharmaceutical Co., Ltd. We systematically reviewed the safety literature of Xingxue~ SXN. Adverse drug reaction(ADR) data of the drug, extracted from Spontaneous Reporting System(SRS), and clinical characters based on 20 hospital information systems(HIS) in China, were analyzed. Large-scale prospective safety monitoring and Risk Minimization Action Plans(Risk MAPs) of Xingxue~SXN were carried out.RESULTS: The quality of SXN was stable and controllable when it was produced. Drug toxicology studies found no effect on rabbits with hemolytic or condensed, local stimulation and muscle stimulation, and no allergic reactions in guinea pigs. The ADRs of Xingxue~ SXN were dizziness, phlebitis,and vomiting based on SRS data. The injection did not conform to instructions in clinical practice when we analyzed HIS database, and patient’s abnormal blood urea nitrogen levels may be related to the drug, when analyzed using the propensity score method. A nested case-control study was designed and performed to analyze the influencing factors of suspected allergic reactions to SXN. The study showed that patients with an allergy history were more prone to allergic reactions(P<0.001),and some medicine combinations could cause allergic reactions.CONCLUSION: These studies have established a body of evidence on Xingxue~ SXN safety, and provide a good model for Chinese medicine injection for clinical safety. The Xingxue~ SXN production process and toxicology research indicate the safety of the injection. However, the use of the injection is not consistent with instructed clinical practice.Xingxue~ SXN causes ADRs perhaps from inappropriate usage or its pharmacological action. This injection needs better Risk MAPs to ensure its clinical safety.
文摘Objective:To study the effect of adjuvant Shuxuening injection therapy on the inflammatory response mediated by TLRs in patients with acute exacerbation of COPD.Methods:Patients with acute exacerbation of COPD who received Shuxuening injection combined with conventional western medicine treatment in our hospital between May 2014 and December 2015 were selected for study, and before treatment as well as 1 week, 2 weeks, 3 weeks and 4 weeks after treatment, peripheral blood mononuclear cells were collected to determine TLRs expression, and serum was collected to determine the levels of inflammatory cytokines and airway remodeling molecules.Results:1 week, 2 weeks, 3 weeks and 4 weeks after treatment, TLR2 and TLR4 mRNA expression in peripheral blood mononuclear cells as well as TNF-α, IL-6, MCP-1, VCAM-1, MMP2, MMP9, TGF-β and BMP-2 levels in serum of patients with COPD were significantly lower than those before treatment, and TLR3, TLR7, TLR8 and TLR9 mRNA expression were not significantly different from those before treatment;TLR2 and TLR4 mRNA expression in peripheral blood mononuclear cells were positively correlated with serum TNF-α, IL-6, MCP-1, VCAM-1, MMP2, MMP9, TGF-β and BMP-2 levels. Conclusion:Adjuvant Shuxuening injection therapy has significant inhibitory effect on the inflammatory response mediated by TLRs in patients with acute exacerbation of COPD.
文摘Background:To systematically evaluate the efficacy and safety of the Chinese patent medicine Shuxuening injection combined with western medicine in vascular dementia treatment.Methods:Randomized controlled trials of the Chinese patent medicine Shuxuening injection in vascular dementia treatment is searched in the databases of CNKI,Wanfang,VIP,CBM,PubMed,The Cochrane Library,Embase and Web of Science from the establishment time to December 2020.After screen the literature,extract the data and evaluate the bias risk of studies included;tRevMan5.3 was used for met-analysis.Results:Nine randomized controlled trials including 932 patients were included.The results of meta-analysis included:(1)the total effective rate(RR=1.27,95%CI(1.18,1.36),P<0.00001);(2)MMSE score(MD=4.78,95%CI(1.75,7.80),P=0.002);(3)ADL score(MD=8.87,95%CI(6.70,11.05),P<0.00001);(4)NIHSS score(MD=−6.60,95%CI(−7.04,−6.16).P<0.00001).The results of meta-analysis of the test group are better than those in the control group.Conclusion:The Chinese patent medicine Shuxuening injection combined with conventional western medicine has showed some advantages in the total effective rate,MMSE score,ADL score,NIHSS score than conventional western medicine without more side effects in vascular dementia treatment.More randomized,double-blind,large sample clinical studies are needed to confirm the above conclusions.
文摘OBJECTIVE: To observe the effect of Shuxuening Injection combined with alprostadil on healing of diabetic foot ulcers and hemodynamic indexes of dorsal artery of foot. METHODS: A total of 84 cases of diabetic foot patients treated in Wuhan Red Cross Hospital(from February 2016 to April 2017) were divided into treatment group(42 cases) and control group(42 cases) by the random digital table. The control group was given basic clinical treatment while the treatment group was given Shuxuening Injection combined with alprostadil on the basis of the treatment in control group. After 2 weeks of treatment, the improvement of TCM symptom scores(pain, numbness, swelling, claudication), conditions of foot ulcer healing(ulcer area, wound oxygen pressure, wound pH), the hemodynamics of the dorsum pedis artery(the blood flow velocity of the dorsum pedis artery, the blood vessel diameter, resistance index(RI), pulsation index(PI)) of both groups were compared, and the clinical efficacy of 2 groups were statistically analyzed. RESULTS: The scores of pain, numbness, swelling and claudication were significantly reduced in 2 groups after the treatment(P < 0.05), and the improvement of the above symptom scores in the treatment group were all significantly better than that in the control group(P < 0.05). The area of ulcer and the p H of the wounds in the 2 groups were significantly decreased after the treatment(P < 0.05), and the oxygen partial pressure in the wound was significantly increased(P < 0.05), and the improvements of the wound healing outcomes in the treatment group were significantly better than that in the control group(P < 0.05). The blood flow velocity of the foot, the blood vessel diameter, the level of RI and PI after treatment in both groups were significantly increased after the treatment(P < 0.05), and the improvement of the hemodynamic index of the foot back after treatment in the treatment group was significantly better than that in the control group(P < 0.05). The total effective rate of the treatment group was significantly higher than that of the control group(P < 0.05). CONCLUSION: The application of Shuxuening Injection combined with alprostadil can quickly improve the clinical symptoms of the patients, correct the abnormal hemodynamics of the dorsum pedis artery and promote the healing of foot ulcers, and the combination of the two medicines has a synergistic effect.
文摘Objective: to observe the clinical effect of intravenous thrombolysis with alteplase combined with Shuxuening injection on ischemic stroke. Methods: selected subjects: 90 patients with acute ischemic stroke in the emergency department of our hospital were selected from March 2021 to August 2022. They were grouped according to the computer parity distribution method, the control group database (45 patients data), and the observation group database (43 patients data), and Shuxuening injection combined with alteplase therapy. To observe the effects of different therapies on the clinical effect, neurological function score, inflammatory value, neurotransmitter and coagulation value of patients. Results: compared with the parameter difference between groups, there was no significant difference in data before treatment (P > 0.05). After treatment, the results of data comparison were significant, the clinical treatment effect of the patients in the observation group was significantly improved, the inflammatory values and neurological function scores were significantly decreased, and the neurotransmitters and coagulation values were significantly improved, P<0.05. Conclusion: the combined therapy of intravenous thrombolysis with alteplase and Shuxuening injection for patients with acute ischemic stroke has a significant clinical effect, which can effectively change the patients condition and improve the inflammatory response and neurological function.
基金Supported by the National Natural Science Foundation of China (No.82274316)the Special Project for the Scientific Research of Traditional Chinese Medicine in Henan Province (No.2022ZYZD01)。
文摘Objective: To investigate the main components and potential mechanism of Shuxuening Injection(SXNI) in the treatment of myocardial ischemia-reperfusion injury(MIRI) through network pharmacology and in vivo research. Methods: The Traditional Chinese Medicine Systems Pharmacology(TCMSP) and Pharm Mapper databases were used to extract and evaluate the effective components of Ginkgo biloba leaves, the main component of SXNI. The Online Mendelian Inheritance in Man(OMIM) and Gene Cards databases were searched for disease targets and obtain the drug target and disease target intersections. The active ingredient-target network was built using Cytoscape 3.9.1 software. The STRING database, Metascape online platform, and R language were used to obtain the key targets and signaling pathways of the anti-MIRI effects of SXNI. In order to verify the therapeutic effect of different concentrations of SXNI on MIRI in rats, 60 rats were first divided into 5 groups according to random number table method: the sham operation group, the model group, SXNI low-dose(3.68 mg/kg), medium-dose(7.35 mg/kg), and high-dose(14.7 mg/kg) groups, with 12 rats in each group. Then, another 60 rats were randomly divided into 5 groups: the sham operation group, the model group, SXNI group(14.7 mg/kg), SXNI+LY294002 group,and LY294002 group, with 12 rats in each group. The drug was then administered intraperitoneally at body weight for 14 days. The main biological processes were validated using in vivo testing. Evans blue/triphenyltetrazolium chloride(TTC) double staining, hematoxylin-eosin(HE) staining, terminal deoxynucleotidyl transferase d UTP nick end labeling(TUNEL) assay, enzyme-linked immunosorbent assay(ELISA), and Western blot analysis were used to investigate the efficacy and mechanism of SXNI in MIRI rats. Results: Eleven core targets and 30 Kyoto Encyclopedia of Genes and Genomes(KEGG) pathways were selected. Among these, the phosphoinositide 3-kinase(PI3K)/protein kinase B(AKT) pathway was closely related to SXNI treatment of MIRI. In vivo experiments showed that SXNI reduced the myocardial infarction area in the model group, improved rat heart pathological damage, and reduced the cardiomyocyte apoptosis rate(all P<0.01). After SXNI treatment, the p-PI3K/PI3K and p-AKT/AKT ratios as well as B-cell lymphoma-2(Bcl-2) protein expression in cardiomyocytes were increased, while the Bax and cleaved caspase 3 protein expression levels were decreased(all P<0.05). LY294002 partially reversed the protective effect of SXNI on MIRI. Conclusion: SXNI protects against MIRI by activating the PI3K/AKT signaling pathway.
文摘Objective： To investigate the efficacy and safety of combined common femoral artery （CFA） endarterectomy with superficial femoral artery （SFA） stenting plus Shuxuening Injection （舒血宁注射液） infusion in patients with complex multifocal arterial steno-obstructive lesions of the lower extremities. Methods： From March 2006 to March 2011, 104 lower limbs in 96 patients with multilevel peripheral arterial steno-occlusive disease, involving SFA as well as CFA and deep femoral artery （DFA） orifice, were treated by combined surgical with endovascular therapy, such as SFA stenting as an adjunct to CFA endarterectomy and patch angioplasty with the great saphenous vein. Before the end of the operation, 20 mL of Shuxuening Injection was infused through the catheter located in the treated artery. Technical and hemodynamic success, as well as primary and primary-assisted patency, was determined according to the Society for Vascular Surgery Guidelines. During follow-up, clinical status assessment, ankle-brachial index （ABI） test, and duplex Doppler ultrasound were administered every 6 months, and computed tomography angiography or magnetic resonance angiography was performed at 12, 24, and 36 months after discharge. Results： All patients underwent successful combined CFA endarterectomy with SFA stenting treatment. The average ABI after the combination treatment increased from pretreatment of 0.32 ± 0.21 to 0.82±0.24 （P〈0.01）. No perioperative death and major limb amputations occurred. The mean duration of follow-up for 104 limbs from 96 patients was 1,180 days （range, 196-2,064 days）. During follow-up, 5 patients died due to myocardial infarction, cerebral infarction, or pneumonia, and 5 patients were lost to follow-up. There were 21 cases （21.4%） of restenosis, with 15 that occurred in-stent and 6 near the dJstal end of the stent. A total of 18 （18.3%） reinterventions were performed, including 6 balloon angioplasty, 8 restenting procedures, 2 bypass surgeries, and 2 major limb amputations： The primary patency rates were 92.2%, 76.8%, and 61.3% at 12, 24, and 36 months, respectively, while the primary-assisted patency rates were 94.4%, 83.2%, and 75.6% at 12, 24, and 36 months, respectively. Conclusion： The combined CFA endarterectomy with SFA stenting plus Shuxuening Injection infusion appears to offer a safe, less invasive, and effective treatment option to patients with chronic lower extremity ischemia due to complex multifocal peripheral artery disease.
文摘Objective: To make a preliminary evaluation of the clinical efficacy of Shuxuening (SXN).Methods: One hundred and forty-nine chronic schizophrenic patients were divided randomly into the SXN group and the control group in a double-blind research. SXN was given to the SXN group and placebo to the control group, and patients of both groups went on receiving the previous antipsychotic treatment. Brief Psychiatric Rating Scale (BPRS), Scale for Assessment of Negative Symptoms (SANS) and Treatment Emergent Symptoms Scale (TESS) were used to assess the effects of treatment and side effects of the drug. The evaluation was done before and during the 2nd, 4th, 6th, 10th and 12 th weeks in the course of treatment. Results: SXN was effective by BPRS evaluation (P ＜0. 05), and even the more effective to negative symptoms than positive symptoms by SANS evaluation (P＜0. 05). It was safe and with little side effect. In addition, it was found that the incipience of SXN ’s efficacy was somehow related with the course of disease and the daily dosage used. Conclusion: SXN is worthy of further study n the treatment of chronic schizophrenia.
基金supported financially by the Guangxi Science and Technology Research Project(GuiKeAA18242040)the National Science and Technology Major Project(2018ZX09735-002)。
文摘Objective:In this study,a comprehensive and effective quality method for evaluating the efficacy of ShuXueNing injection(SXNI)was developed.Materials and Methods:Quantitative high-performance liquid chromatography fingerprint,the quantitative analysis of multicomponents by a single marker(QAMS)method,hierarchical cluster analysis(HCA),and orthogonal partial least squares discrimination analysis(OPLS-DA)were used to distinguish 53 batches of SXNI samples from 7 manufacturers.Results:A total of 53 batches of samples were analyzed to establish antithesis fingerprint of SXNI,and 12 peaks of the common model were collected and used for the similarity analysis.Meanwhile,six index flavonoid components were determined by the QAMS method,using rutin as internal reference substance.The accuracy of the QAMS method was confirmed by investigating the relative deviation between the QAMS method and the traditional external standard method.The results demonstrated that there was no significant difference(RE<1%),suggesting that QAMS was a reliable and convenient method for the content determination of multiple components.The HCA and OPLS-DA methods drew a similar conclusion.The 53 batches of SXNI samples from 7 manufacturers were categorized into five groups,indicating that chemometrics could reveal the quality differences of SXNI between the manufacturers.Conclusions:The method established herein was efficient and successful in assessing the quality of SXNI,and that it may be potentially employed in the quality control of related products composed of Ginkgo biloba extract.
